Amendment No. 1 to the CIRM Award, dated August 8, 2017
Exhibit 10.1
AMENDMENT TO NOTICE OF AWARD – CLIN 2 - CIRM Clinical Trial Stage Projects
California Institute for Regenerative Medicine
Amendment Number: 01
Amendment Date: 8/8/17
Award Number: | CLIN2-08334 | Total Award Amount: | $3,376,259 |
Awardee Name: | Capricor, Inc | Project Period Start Date: | 04/01/2016 |
Project Period End Date: | 10/31/2018 | ||
Principal Investigator or Program Director: | Deborah Davis Ascheim
| ||
Project Title: | Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy |
Authorized Organization Official and Address: | Official and Address to Receive Payments: |
AJ Bergmann | AJ Bergmann |
VP of Finance | 8840 Wilshire Blvd., 2nd Floor |
8840 Wilshire Blvd. 2nd Floor | Beverly Hills, CA 90211 |
Beverly Hills, CA 90211 |
This Amendment responds to the Prior Approval Request (PAR) dated and/or received by CIRM on 07/14/2017. The terms and conditions of the original NGA and any prior Amendments to the NGA continue in full force and effect except for those changes specified in this amendment. The Principal Investigator and Authorized Organizational Official must sign and return this Amendment to CIRM within 30 days of the Amendment date stated above. CIRM may hold future payments on this Award until the fully signed Amendment is received. The following changes are effective immediately:
A. | Change in Scope, Specific Aims, or Milestones |
Request to use existing project funds for tech transfer of manufacture of the CAP-1002 product to designated CMO, approved by CIRM, which will enable them to offer access to CAP-1002 to patients from the control arm of the ongoing study (HOPE) via an open-label extension protocol (subject to regulatory approval), is approved.
By continuing to accept and use CIRM funds provided under this award, Grantee and Principal Investigator accept the modified terms reflected in this Amendment.
/s/ Maria Millan, M.D. | |
Maria Millan, M.D. | |
Vice President, Therapeutics, CIRM | |
/s/ Deborah Davis Ascheim | |
Deborah Davis Ascheim | |
Principal Investigator, Capricor, Inc | |
/s/ AJ Bergmann | |
AJ Bergmann | |
Authorized Organization Official, Capricor, Inc |